HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 41, 30400-30411, October 13, 2006

This Article Abstract Full Text (PDF) All Versions of this Article: 281/41/30400    most recent M603321200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Cristofaro, R. Articles by Mannucci, P. M. Search for Related Content PubMed PubMed Citation Articles by De Cristofaro, R. Articles by Mannucci, P. M. Social Bookmarking                      What's this?

Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF)

ENERGETICS AND CONFORMATIONAL EFFECTS ON THE VWF/ADAMTS-13 INTERACTION^*

Raimondo De Cristofaro¹, Flora Peyvandi, Luciano Baronciani, Roberta Palla, Silvia Lavoretano, Rossana Lombardi, Enrico Di Stasio^¶, Augusto B. Federici, and Pier Mannuccio Mannucci

From the Hemostasis Research Centre, Institute of Internal Medicine and Geriatrics, Catholic University School of Medicine, 00168 Rome, A. Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan, and the Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, 20122 Milan, and ^¶Institute of Biochemistry and Clinical Biochemistry, Catholic University School of Medicine, 00168 Rome, Italy

Received for publication, April 7, 2006 , and in revised form, August 8, 2006.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Physiological concentrations of NaCl inhibit the hydrolysis of von Willebrand factor (VWF) by ADAMTS-13. This effect is because of the specific binding of chloride ions to VWF. Urea-induced unfolding was measured in the presence of NaCl, CH₃COONa, and NaClO₄ at pH 8.0, 25 °C, for multimeric VWF, the recombinant A1-A2-A3 VWF domains, and the A1 domain. Chloride stabilizes the folded conformation of the A1-A2-A3 and A1 domains more efficiently than acetate but less strongly than perchlorate. Spectroscopic evidence showed that chloride binds to both the A1 and A1-A2 domain but not to the isolated A2 domain. Binding of Cl^– to both wild type (WT) and the natural mutant p.R1306W A1-A2-A3 domains of VWF has a large heat capacity change equal to –1 and –0.4 kcal mol^–1 K^–1 for WT and p.R1306W A1-A2-A3 domains, respectively. This result implies that a burial of a vast apolar surface area is caused by conformational transitions linked to chloride binding. At any temperature, chloride affinity was higher for WT than for the mutant p.R1306W form. Chloride ions inhibit hydrolysis by ADAMTS-13 of the A1-A2-A3 and A1-A2 domains in the presence of either urea or high shear stress, whereas this effect was either absent or negligible in experiments using A2 and A2-A3 domains. These findings show that the A1 domain contains the binding site of chloride ions that control allosterically the proteolysis by ADAMTS-13 of the Tyr¹⁶⁰⁵–Met¹⁶⁰⁶ bond in the A2 domain and that the R1306W mutation of type 2B VWD quenches the binding of chloride ion to the A1 domain.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The degradation of von Willebrand factor (VWF)² depends on the activity of the zinc protease ADAMTS-13, which cleaves this multimeric adhesive protein at the peptide bond between residues Tyr¹⁶⁰⁵ and Met¹⁶⁰⁶ of the A2 domain (1–5). In contrast with other zinc proteases, such as the matrix metalloproteases, ADAMTS-13 does not need activation by other hydrolases to become proteolytically competent toward VWF (1). Hence this protease must be regulated by other factors to avoid the continuous cleavage of high molecular weight VWF multimers, which play a key role in primary hemostasis. The regulatory mechanisms of the VWF/ADAMTS-13 interaction are linked to the high conformational mobility of VWF. The adhesion of platelets to the vessel wall, under the high flow/shear conditions of blood in the microcirculation, is mediated by VWF and in particular by sequences within the A1 and A3 domains. The A1 domain (residues 1260–1479) binds to the platelet glycoprotein Ib·IX·V complex (GpIb), to subendothelial glycosaminoglycans, to sulfatides of the cell surface (6), and to nonfibrillar collagen type VI (7). Native VWF in blood has no appreciable binding to platelets. This interaction can take place by means of such exogenous nonphysiologic modulators as ristocetin and botrocetin (8, 9) and by fluid shear stress (5, 10) or can be the consequence of gain-of-function mutations in the A1 domain causing type 2B von Willebrand disease (VWD) (11, 12). It is generally assumed that the modulation of GPIb binding activity involves conformational changes in VWF that lead to the exposure of functional sites normally cryptic when the molecule is in solution. In vivo, this may occur under high shear stress (5, 10) or when VWF interacts with such subendothelial components as collagen after the integrity of the vessel wall is disrupted (13). The formation of VWF-GpIb complex was recently found to accelerate the specific cleavage of VWF by ADAMTS-13 (14). This finding implies that the conformation of the A1 domain regulates through allosteric mechanisms the accessibility of the ADAMTS-13 cleavage site in the A2 domain of VWF. On the other hand, the VWF A-like domain is conserved in several plasma and matrix proteins involved in different biological functions and is now considered the prototype for a protein superfamily containing at least 75 proteins that are similar in sequence (15). For many of these proteins the VWF A domain is characterized by a strong ability to transmit allosteric signals in virtue of its high conformational mobility (16, 17). The hydrolysis of VWF can be obtained in vitro under static conditions, using a mild denaturing milieu, which generates partially unfolded VWF conformers that are susceptible to proteolytic attack by ADAMTS-13. Moreover, early studies by Furlan et al. (2), recently extended by our group (17) on the specificity of the VWF/ADAMTS-13 interaction showed that physiological concentrations of NaCl inhibit allosterically the hydrolysis of VWF in the presence of mild denaturing urea concentrations. We largely ascribed this effect to the specific binding of chloride ions to VWF (17), but the molecular mapping of the anion-binding site is still elusive. The goal of this study was to assess within the A1-A2-A3 domains of VWF the effect of chloride binding on the unfolding of the protein and on its conformational stability. A further goal of the study was to map the binding site of chloride ions within the A1-A3 domains and to analyze the allosteric linkage with the hydrolysis of the Tyr¹⁶⁰⁵–Met¹⁶⁰⁶ peptide bond in the A2 domain. The natural type 2B VWD mutant, p.R1306W VWF, was also used to investigate how this mutation is allosterically linked to both chloride binding and to the efficiency of VWF hydrolysis by ADAMTS-13.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Production of Vectors Containing A1-A2-A3 and A1-A2 VWF cDNA
Step 1—The sequence encoding domains A1, A2, and A3 was amplified with designed primers (set A) available on request, using as a template the pSV-VWFH vector, a kind gift of Lysiane Hilbert and Claudine Mazurier (Lille, France), which contains the full-length human VWF cDNA (18). The PCR product was purified and digested with AvrII and EcoRV (New England Biolabs, Beverly, MA) and then ligated into pSV-VWFH vector, which had been digested with the same enzymes, in order to obtain the pSV-A1A2A3V5 vector.

Step 2—The construction of the pSV-SPHA1A2A3V5 cloning vector, containing also the VWF signal peptide and the His₆ tag sequence, required a second PCR (PCR condition and primers, set B, are available on request). The pSV-VWFH was used as a template, and the PCR product was purified, digested with AvrII and Tth111I, and ligated into the pSV-A1A2A3V5 vector, which had been digested with the same enzymes.

Step 3—The pSV-SPHA1A2A3V5 vector was further amplified with designed primers available on request (set C). The PCR product was purified and digested with HindIII and EcoRV and then ligated into the pcDNA3.1 mammalian expression vector (Invitrogen), which had been digested with HindIII and PmeI, in order to obtain the pcDNA3.1SPHA1A2A3V5 vector. The ligation was feasible because both EcoRV and PmeI cause blunt ends.

Step 4—The p.R1306W mutation was introduced into pcDNA3.1SPHA1A2A3V5 using a QuikChange^TM site-directed mutagenesis kit (Stratagene, La Jolla, CA). A forward primer (5'-GGACATGATGGAGTGGCTGCGCATCTCC-3') and a reverse primer (5'-GGAGATGCGCAGCCACTCCATCATGTCC-3') were used to introduce c.3916C > T (designated as T), to obtain pcDNA3.1SPHA1A2A3V5-R1306W.

Step 5—A small portion of pcDNA3.1SPHA1A2A3V5 vector, containing a short sequence of the A2 domain and the V5 tag sequence, was amplified (primer set D available on request). The product of this PCR was purified, digested with BspEI and DraIII, and then ligated into pcDNA3.1SPHA1A2A3V5 vector, which had been digested with the same enzymes, in order to obtain pcDNA3.1SPHA1A2V5. Cloned inserts were sequenced to confirm the correct sequence (19).

Transient Transfection of Wild Type (WT) and Mutant VWF Fragment Expression Vectors
Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium enriched with nutrient mixture F-12 supplemented with 10% fetal bovine serum, 2 mmol/lite L-glutamine, and 100 mg/ml penicillin/streptomycin (Invitrogen) in a 5% CO₂ atmosphere at 37 °C. Approximately 5 x 10⁶ HEK293 cells were independently transfected with pcDNA3. 1SPHA1A2A3V5, pcDNA3.1SPHA1A2A3V5-R1306W, and pcDNA3.1SPHA1A2V5 expression vectors by using a method described previously (20). Serum-free conditioned medium was applied to confluent cells 14 h after transfection, collected after additional 72 h, and added with phenylmethylsulfonyl fluoride (Sigma) to a final concentration of 1 mM.

Production and Expression of Recombinant A2 and A2-A3 VWF Fragments
The sequence encoding domains A2 and A2-A3 were amplified with primer sets E and F, respectively (available on request), using as a template the pcDNA3.1SPHA1A2A3V5 vector. The PCR product obtained with primer set E was purified, digested with XhoI and HindIII, and then ligated into pRSET-A (Invitrogen) vector, which had been digested with the same enzymes, in order to obtain the pRSET-A2V5 vector. The PCR product obtained with primer set F was purified and digested with the KpnI and HindIII and then ligated into the pRSet-A2V5 vector, which had been digested with the same enzymes in order to obtain the pRSET-A2A3V5 vector. Both pRSET-A2V5 and pRSET-A2A3V5 vectors were expressed in BL21 Escherichia coli cells (Invitrogen). Transformed bacteria were grown in LB broth at 37 °C and shaken. Recombinant protein production was induced with 1 mM isopropyl -D-thiogalactoside overnight. Bacteria were harvested and lysed using CelLytic^TM Express (Sigma) reagent, and the soluble fraction was collected.

Purification of VWF Fragments
Conditioned media of transfected HEK293 and the soluble fraction from bacteria were dialyzed into phosphate-buffered saline overnight at 4 °C, and recombinant proteins were purified on a nickel-chelated agarose column (Pierce) according to manufacturer's instructions. Purified proteins were dialyzed into 10 mM Hepes, pH 7.0, overnight at 4 °C. Recombinant proteins were analyzed by SDS-PAGE and Coomassie staining, and the concentration was quantified using a protein assay (Bio-Rad) and spectrophotometrically at 280 nm, using extinction coefficients (g/liter) of 0.574, 0.682, 0.999, 0.612, and 0.548 for WT A1-A2-A3, p.R1306W A1-A2-A3 mutant, A2, A1-A2, and A2-A3 domains, respectively. The A2-A3 domains obtained from the above procedure under nonreducing conditions showed a series of bands with a molecular mass of greater than 48 kDa (not shown). Western blot analysis showed that all these bands reacted with rabbit horseradish peroxidase-labeled polyclonal anti-VWF antibody from Bethyl Laboratories, Inc. (Prodotti Gianni, Milano, Italy). These bands disappeared under reducing conditions, where a single band of 48 kDa showed up. This finding suggested that several constructs randomly stem in bacteria from the folding process, using different arrangements of the free cysteine residues present in the construct. Thus, a further purification was performed by RP-HPLC using a C4 column (5–60% CH₃CN in 0.1% trifluoroacetic acid in 40 min). The peaks corresponding to the 48-kDa species were dried under vacuum and resuspended in 10 mM Hepes, pH 7.50. Finally, to check the correct folding of this species, a collagen binding assay (Life Therapeutics, Cabru, Peregallo di Lesmo, Italy) was performed on this material and compared with the behavior of purified A1-A3 and isolated A2 domains, knowing that only the A1 and A3 domains interact with equine tendon collagen (7). The assay confirmed that the A2 domain did not interact with immobilized collagen, whereas 0.05–0.15 mg/ml of both A1-A2-A3 and A2-A3 bound to collagen with progressively higher avidity (in both cases an absorbance value of >5-fold with respect to blank at 0.05 mg/ml). This finding showed that the A2-A3 domains support significant binding to collagen, strongly suggesting that the HPLC-purified A2-A3 domains folded correctly.

Purification of Blood-derived Full-length VWF and the 39/34-kDa A1 Domain
Multimeric VWF—Pharmaceutical preparations of VWF concentrates (Fahndi, Grifols, Ghezzano, Italy) were used as source material to purify VWF. Briefly, 20,000 units of preparation were suspended in 20 ml of distilled water and filtered using 2-µm pore-sized membranes. This solution was gel-filtered at a flow rate of 2.0 ml/min onto a 70 x 2.6 cm Sephacryl S500 column equilibrated with 10 mM Tris-HCl, 0.15 M NaCl, pH 8.0, at 25 °C to eliminate albumin present in the preparation. The peak containing VWF was pooled and passed through a heparin-Sepharose column (25 x 1.5 cm; Amersham Biosciences) equilibrated in the same buffer at a flow rate of 0.8 ml/min. A gradient of 0.1–0.5 M NaCl was applied for 60 min. The last peak to be eluted (0.29 M NaCl) was pooled, and aliquots were stored at –80 °C. SDS-PAGE of this material showed under reducing conditions the existence of a single band with an apparent molecular mass of about 230 kDa. The concentration of this purified material was measured by a standardized method using a commercial kit for VWF antigen (Instrumentation Laboratory, Milan, Italy) and an automatic instrument (Instrumentation Laboratory). By using the same instrument and a commercially available assay (VWF activity; Instrumentation Laboratory), the ratio between VWF antigen and ristocetin cofactor activity (expressed as percentage) was equal to 1.05, demonstrating that the purified protein had an intact functional activity. Accordingly, purified VWF showed a 110% aggregating activity at 10 µg/ml (final antigen concentration) in a ristocetin-induced platelet aggregation assay using 1.5 mg/ml ristocetin in a PACK-4 aggregometer (Helena Laboratories).

A1 Domain (39/34-kDa VWF)—A 39/34-kDa fragment of VWF, expressing the A1 domain of the protein (21), was produced by dispase (Roche Applied Science) digestion of human VWF, purified as described above. This fragment encompasses residues from Leu¹²⁴³ to Gly¹⁴⁸¹ (239 residues). Briefly, VWF (1 mg/ml) in 0.01 M Tris, 0.15 M sodium chloride, 0.2 mM calcium chloride, pH 7.4, was equilibrated with dispase (0.3 mg/mg of VWF) for 6 h at 25°C. The reaction was terminated by the addition of EDTA (10 mM final concentration). The digest was then loaded at 0.4 ml/min onto a 1.5 x 5-cm column of heparin-Sepharose (Amersham Biosciences) equilibrated at 25 °C in 10 mM Tris, 0.15 M sodium chloride, pH 7.4. After washing, the 39/34-kDa VWF fragment was eluted with 0.01 M Tris, 0.5 M sodium chloride, and 0.02% (w/v) sodium azide, pH 7.4, and dialyzed against TBS at 4 °C. The identity of the isolated 39/34-kDa VWF fragment was confirmed by SDS-PAGE on a 4–12% gradient gel (Bio-Rad) and a Criterion apparatus (Bio-Rad) and by an N-terminal sequence performed on an automatic analyzer (Applied Biosystems), which found for both the 39- and the 34-kDa bands the sequence Leu-Val-Val-Pro-Pro-Thr, corresponding to the residues 1243–1248 of VWF, as found previously (21). The difference in molecular weight was attributed to a different O-glycosylation pattern as demonstrated in previous studies (21). The purified 34/39-kDa fragment was used in the spectroscopic experiments without further separation.

Expression and Purification of Recombinant ADAMTS-13
Full-length human ADAMTS-13 was expressed and purified as reported previously (17). SDS-PAGE on 4–12% gradient gels showed that under reducing conditions the purified material consisted of a single band of 170 kDa.

Urea-induced Unfolding Experiments Monitored by Intrinsic Protein Fluorescence
Urea-induced unfolding curves were fitted to a two-state equation, as described previously (22), to calculate the thermodynamic parameters G, C_m, and m. The observed free energy of unfolding, G, is assumed to be a linear function of urea molarity with G =G⁰ – m[U], where m represents the sensitivity of the transition to the urea concentration, and G⁰ is the free energy of unfolding in the absence of denaturants at a standard state of 1 M. Another derived parameter, U, defined as the ratio (G⁰/m), is the concentration of urea where the fraction of unfolded protein equals that in the native state. The values of these parameters and their standard deviations are the average of at least two unfolding experiments. For each determination of the unfolding free energy under a particular set of salt conditions, increasing urea concentrations were analyzed by adding stepwise to VWF and its A domains a stock urea solution (9 M) buffered with 5 mM Tris-HCl, pH 8.00, at 25 °C. The recorded fluorescence spectra were corrected for the contribution of urea alone and the dilution factor of the protein solution. The extent of denaturation was monitored at 25 °C by tryptophan and tyrosine fluorescence at 337 nm on a thermostated spectrofluorometer (Varian Cary Eclipse) with an excitation wavelength of 295/280 nm (5 nm bandpass at both excitation and emission wavelength).

Specifically, fluorescence intensity (F) as a function of urea concentration ([U]) was fitted to Equation 1,

(Eq. 1)

where G and m are the intercept and slope, respectively, of the linear extrapolation of the unfolding free energy to zero urea concentration; F_0N and s_N are the intercept and slope, respectively, of the native state base line; F_0D and s_D are their counterparts of the denatured state base line, and k_B and T are the Boltzman's constant and the absolute temperature. Each sample, thermostated at 25 °C, was allowed to equilibrate for at least 15 min, and the final VWF and the concentration of its domains were always 0.1 mg/ml, to avoid inner filter effects.

Fluorescence experiments of guanidine chloride-dependent unfolding were also performed to demonstrate the applicability of the two-state model of unfolding for the A1-A2-A3 domain.

Data were analyzed by the linear extrapolation method, using GRAFIT (Erithacus Software, Horley Surrey, UK). To study the effect of salts on G, samples with the same concentration of salts were prepared in duplicate, and fluorescence data sets in the different repeats were fitted to Equation 1 with G, m, F_0N, s_N, F_0D, and s_D as specific to a particular data set. Standard errors of fitting parameters were calculated along with the best fit values.

Temperature Dependence of Cl^– Interaction with the A1-A2-A3 Domains of VWF
The temperature dependence of Cl^– binding was analyzed by change of the intrinsic fluorescence of the various VWF domains, as reported previously (17). The experiments were performed over a temperature range from 7 to 40 °C, in a 5 mM Tris-HCl buffer, pH 8.0, at all temperatures. The pH' of the buffer solution was always set at 25 °C, using a pH/T value of Tris buffer of –0.027. In some experiments, intrinsic fluorescence of the A1-A2-A3 domains was studied as a function of unfractionated heparin (from porcine intestinal mucosa; Calbiochem) up to a concentration of 10 µM. The thermodynamic parameters of binding were calculated using the van't Hoff analysis and fitting for Cp, T_H, and T_S, contained in Equation 2, which assumes a large negative heat capacity change (23),

(Eq. 2)

where C_p is the heat capacity change, and T_H and T_S define the characteristic temperatures where the enthalpic (H) and entropic (S) contributions to the free energy change are 0, respectively.

Hydrolysis of Recombinant VWF Constructs by rADAMTS-13
Recombinant ADAMTS-13 (final reaction concentration 5–10 nM) was incubated in 5 mM Tris-HCl, 1.5 M urea, 3 mM BaCl₂, NaCl from 0 to 0.15 M, pH 8.0, at 25 °C with 0.05 mg/ml of purified A1-A2-A3 (WT and p.R1306W), A1-A2, A2-A3, and A2 domains of VWF. In the latter case urea was omitted from the buffer solution, because the denaturant partially inhibits the protease activity of ADAMTS-13. At different time points, 50 µl of the samples were removed; the reaction was stopped with 10 mM EDTA, and the reaction products were analyzed by RP-HPLC. Samples were analyzed by means of a 250 x 4.6-mm RP-304 column (Bio-Rad). The chromatographic run was performed by applying the following conditions: 5% acetonitrile for 5 min, from 5 to 60% acetonitrile in 0.1% trifluoroacetic acid for 60 min for A1-A2-A3 domains and 40 min for the A2 domain, whereas the acetonitrile gradient was 20% for 5 min and from 20 to 65% in 45 min for the A1-A2 and A2-A3 fragments. The peaks were detected routinely at 214 or 254 nm.

For the shear stress experiments, a cone-plate rheometer (model CSL 500) from Carrimed (now TA Instruments, Waters S.p.A., Vimodrone, Italy) was used. The used cone had a diameter of 4 cm and the cone-plate gap was of 10 µm. The experimental conditions used were 5 mM Tris-HCl, 3 mM BaCl₂, t either 0.01 or 0.15 M NaCl, pH 8.0, at 37 °C. The purified A1-A2-A3 domains of VWF were used at 0.05 mg/ml, whereas recombinant ADAMTS-13 was employed at 10 nM. To ensure achievement at the desired temperature, samples were applied on the cone-plate apparatus for about 1 min under static conditions. The shear stress applied was either of 0 or 40 dynes/cm², corresponding from the geometry of the system (0.2°) to a shear rate ranging from 818 to 850 s^–1. The total volume of the applied sample was of 344 µl. The shear was applied for 1 or 5 min. At the end, the cone-plate was stopped; the entire volume of the sample was recovered, and 10 mM EDTA (final concentration) was added to the solution to stop the reaction. The fragments produced by ADAMTS-13 were identified and quantified by RP-HPLC as described above. To check the specificity of the shear-induced VWF cleavage by ADAMTS-13, a control experiment was performed under the same experimental conditions except for the presence of 10 mM EDTA, and no significant VWF hydrolysis was observed. In the kinetic study with 1.5 M urea, in virtue of the pseudo-first order conditions (concentration <K_m of the reaction), the percent of the peptide cleaved at time = t, P_t(%), was fitted to Equation 3,

(Eq. 3)

k_obs is the pseudo-first order rate of its hydrolysis, equal to e₀ k_cat/K_m (e₀ is the ADAMTS-13 concentration). The calculated k_obs values were subsequently analyzed as a function of chloride concentration. The experimental data were analyzed on the basis of Scheme 1,

SCHEME 1

where E is ADAMTS-13; S is the VWF substrate; Cl^– is chloride, and P₁/P₂ are the N- and C-terminal peptides produced by hydrolysis of the peptide bond between Tyr¹⁶⁰⁵ and Met¹⁶⁰⁶. Chloride acts as effector, whose binding and dissociation from VWF was considered much faster than that of VWF to the enzyme. Under these conditions, the pseudo-first order of the ADAMTS-13/VWF interaction, k_obs, was analyzed by the following linkage Equation 4 (17),

(Eq. 4)

where Z is equal to (1 + (Cl^–/K_d)), k⁰, and k^Cl are pseudo-first order rate constants of hydrolysis pertaining to the Cl^–-free and Cl^–-bound VWF domain, and K_d is the equilibrium dissociation constant of chloride binding to VWF domain.

View larger version (9K): [in this window] [in a new window]   FIGURE 1. Schematic showing the structure of the A1, A2, A1-A2, A2-A3, and A1-A2-A3 domains used in this study. The carbohydrate moiety of the A1 domain is not shown.

View larger version (16K): [in this window] [in a new window]   FIGURE 2. Urea- (•) and guanidine-induced () unfolding of WT A1-A2-A3 domains of VWF in the absence of NaCl. The continuous lines were drawn according to Equation 1 with the best fit parameter values as reported in Table 1 for urea data set, whereas G0 = 5.79 ± 0.06, m = 1.9 ± 0.02, sN = 1.8 ± 0.09, F0 = 235.5 ± 0.9, and FU = 190.2 ± 0.9 for the guanidine data set.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Dependence on Salt Concentration of Free Energy for Urea-induced Unfolding of VWF Constructs—Urea-induced unfolding was measured versus NaCl, CH₃COONa, and NaClO₄ concentration at pH 8.0, 25 °C, for full-length VWF, recombinant A1-A2-A3 domains, and purified A1 domain. First, the unfolding free energy G was measured versus urea molarity at a fixed salt concentration and extrapolated back to 0 M urea to give the free energy change associated with unfolding of VWF constructs under nondenaturing conditions. This procedure is repeated at a series of salt concentrations, and G⁰ value is plotted versus [salt]. Control experiments with guanidine chloride were also carried out to validate the correctness of the two-state unfolding model. As shown in Fig. 2 in the absence of NaCl the pre- and post-unfolding fluorescence base lines extrapolated to zero denaturant give the same values regardless of which denaturant is used. This finding demonstrates that the two-state approach is consistent with the experimental data. This means that the difference in fluorescence values between native and unfolded proteins is really a property of the protein, independent of the degree of unfolding cooperativity (m values) calculated from application of Equation 1. However the effect of chloride on the thermodynamics of unfolding of the A1-A2-A3 domain could be studied using urea alone, in consideration of the equimolar concentration of chloride present in the guanidine preparation. In Fig. 3, the spectroscopic data pertaining to unfolding by urea of full-length VWF, the A1-A2-A3 and A1 domains, are shown under the two NaCl concentrations (0–150 mM). It is known that the exposure to solvent water of aromatic amino acids leads to a decrease of their fluorescence intensity because of the quenching effect of water molecules (24). However, this principle can be apparently violated in some proteins, where the interactions between tryptophan and tyrosine residues in the buried region of the folded molecule lead to their mutual quenching, determining an unchanged or increased fluorescence intensity after partial or full unfolding (24). In this study, both constant and increased fluorescence intensity were recorded as a function of salt concentrations in the pre-unfolding segment of the curve (Fig. 3). In the latter case the increase in intensity could be explained only if the mutual quenching of aromatic residues in a folded conformation of the molecule is stronger than the quenching effect of the solvent. This effect, observed for both full-length VWF and the A1-A2-A3 domains, was always observed in the absence of NaCl, whereas physiologic concentrations of the salt eliminated this effect (Fig. 3, A and B). In contrast, the increase of fluorescence change in the absence of NaCl was not observed in the A1 domain (Fig. 3C). The fluorescence changes observed as a function of urea represent a real denaturation process, because a progressive increase of the emission wavelength (>350 nm) at all NaCl concentrations was always observed using urea concentrations >1 M (data not shown). Furthermore, similar results were obtained by exciting the protein solutions at 280 nm instead of 295 nm and fitting the experimental data to Equation 1 (data not shown). NaCl increases the stability to urea denaturation, expressed by the U parameter, of both A1-A2-A3 and A1 domains, although this effect was not observed for full-length VWF, which is probably affected by interchain apolar bonds not sensitive to salt effects (see Table 1 and Fig. 4). In all the VWF forms studied, the value of G⁰ was progressively enhanced by NaCl, as reported in Table 1 and shown in Fig. 5. This parameter describes the free energy change linked to the stability of the protein under nondenaturing conditions, so that this finding implies that chloride ions stabilize a "super-folded" conformation of VWF forms in solution. Moreover, NaCl induces in both the A1-A2-A3 and A1 domains a moderate but significant increase of the m value (see Table 1). Because the m value reflects, at least in part (25), the protein surface area newly exposed on denaturation, the above finding might suggest that in the presence of chloride ions urea induces an exposition to bulk solvent of a higher surface area upon denaturation of the VWF A domains. This finding is in agreement with the hypothesis that chloride ions stabilize a super-folded conformation of the A1 and A1-A2-A3 domains, different from that of the chloride-free protein forms. Altogether these findings demonstrate that chloride ions affect the G⁰ values of all the VWF forms studied, indicating a conformational effect of the anion on VWF species under native conditions. The linkage between the G⁰ values and NaCl is substantially driven by the structural and functional properties of the smallest VWF fragment studied, i.e. the A1 fragment encompassing the amino acid residues Leu¹²⁴³ to Gly¹⁴⁸¹. This conclusion was also corroborated by the finding that the isolated A2 domain does not change its intrinsic fluorescence in the presence of NaCl, whereas both A1-A2 and A1-A2-A3 domains decrease their fluorescence as a function of chloride ions (see below). The potential misfolding of the A2 domain as cause of the lack of chloride binding and subsequent spectroscopic signals could be reasonably ruled out by the finding that the k_cat/K_m value of its hydrolysis by ADAMTS-13 was similar to that calculated for the A1-A2-A3 domains (see below).

View larger version (15K): [in this window] [in a new window]   FIGURE 3. Urea-induced unfolding of different VWF forms. A, full-length VWF; B, A1-A2-A3 construct; C, 39/34-kDa VWF fragment. The excitation wavelength was 295 nm, whereas the emission wavelength was 337 nm. The open symbols refer to the experiments performed in the absence of NaCl, whereas the full symbols are obtained in the presence of 150 mM NaCl. The concentration of the various species were as follows: A, 0.1 mg/ml in the absence of NaCl and 0.089 mg/ml in the presence of 150 mM NaCl; B, 0.11 mg/ml in the absence of NaCl and, 0.088 mg/ml in the presence of 150 mM NaCl; C, 0.118 mg/ml in the absence of NaCl and 0.117 mg/ml in the presence of 150 mM NaCl. The spectral bandwidth was equal to 5 nm in both excitation and emission wavelength. The continuous lines were drawn using the best fit parameter values contained in Equation 1 and listed in Table 1.

View larger version (11K): [in this window] [in a new window]   FIGURE 4. Values of U of unfolding for both A1 (•) and A1-A2-A3 () domains of VWF calculated as a function of chloride concentration at 25 °C, according to the best fit values listed in Table 1.

View larger version (16K): [in this window] [in a new window]   FIGURE 5. The free energy of urea-induced unfolding of VWF A1-A2-A3 domain in kcal/mol, extrapolated to zero urea concentration and plotted against anion molarity (sodium salts): acetate (•), chloride (), and perchlorate (). Conditions are as follows: pH 8.0, 25 °C, 5 mM Tris. The data are fitted by linear regression according to the best fit parameters values: acetate, G0 = 5.506 ± 0.08 kcal mol–1, slope = 10.8 ± 1.1 kcal mol–1 M–1 (r = 0.98); chloride, G0 = 5.74 ± 0.14 kcal mol–1, slope = 28.2 ± 1.9 kcal mol–1 M–1 (r = 0.99); perchlorate, G0 = 5.8 ± 0.2 kcal mol–1, slope = 63.5 ± 3.4 kcal mol–1 M–1 (r = 0.99).

View larger version (15K): [in this window] [in a new window]   FIGURE 6. A, fluorescence titration data of chloride binding to purified WT A1-A2-A3 domain of VWF at 7 °C (), 25 °C (•), and 37 °C (). The continuous lines were drawn to best fit parameter values of Equation 5: Kd = 12.1 ± 0.4 mM, F% = 14.8 ± 0.2% (), Kd = 48 ± 4 mM, F% = 11.2 ± 0.5% (•), and Kd = 197 ± 1 mM, F% = 9 ± 0.2% (). For comparison, data pertaining to the A1-A2 complex at 25 °C are also shown (); the relative best fit parameters values obtained from the fitting procedure are Kd = 39 ± 3 mM, F% = 10.7 ± 0.7%. B, van't Hoff plot of WT (), and p.R1306W A1-A2-A3 domain (•) of human VWF. The continuous lines were drawn to the best fit parameter values of Eq. 2: Cp =–1.05 ± 0.18 kcal mol–1 K–1, TH = 279 ± 1 (K), TS = 281 ± 0.9 (K) for WT A1-A2-A3 domain; Cp =–0.4 ± 0.02 kcal mol–1 K–1, TH = 277 ± 0.5 (K), TS = 280 ± 0.3 (K) for p.R1306W A1-A2-A3 domain.

(Eq. 5)

where F_obs(%) is the experimental value of fluorescence measured as a function of NaCl concentration ranging from 0 to 0.225 M depending on the temperature varying from 7 to 40 °C; F% is the % decrease of the fluorescence at any NaCl concentration, and K_d is the phenomenological equilibrium dissociation constant of chloride binding to any domain of VWF. In all instances a single site binding isotherm was adequately fitted to the experimental data, as shown by Fig. 6A. Although a single site binding isotherm was sufficient to analyze the data, the experimental strategy, in the absence of more detailed structural data, does not allow us to rule out completely that multiple binding sites with a similar affinity for chloride ions are present in the A1-A2-A3 and A1-A2 domains. At all temperatures the apparent affinity of chloride for the WT A1-A2-A3 was higher than that for the mutant p.R1306W A1-A2-A3 domains. Once the K_d value was calculated at each temperature, a van't Hoff plot allowed us to calculate the relevant thermodynamic parameters contained in Equation 2. Fig. 6B shows this plot and reports the best fit parameter values of A1-A2-A3 domains. The experimental points are not linearly correlated with the temperatures values but show a downward curvature, implying that the enthalpy of interaction is not constant over the temperature range studied (7–40 °C) or, in other words, that a large negative heat capacity change characterizes chloride binding to A1-A2-A3 domains. Such a negative heat capacity change is not expected for a purely electrostatic interaction and indicates that hydrophobic and other interactions are also involved in the binding equilibrium. A large heat capacity change was measured for both the WT and the p.R1306W mutant A1-A2-A3 domains, although the value of the WT was double that of the mutant construct (–1.05 ± 0.18 kcal mol^–1 K^–1 versus –0.4 ± 0.02 kcal mol^–1 K^–1). The change in heat capacity associated with any protein/ligand interaction is a fundamental energetic parameter because it provides insight into the hydration changes involved and also affords a key to the correct interpretation of the rest of the energetic parameters in structural terms. The change in heat capacity caused by protein/ligand interaction reflects mainly the contribution from hydration or interaction with the solvent. By analyzing a large set of data with model compounds and structural analysis of the energetics of protein denaturation, a quantitative relation between the C_p (expressed in cal·K^–1·mol^–1) and the change in water-accessible surface area of buried apolar residues was formulated as shown in Equation 6 (29),

(Eq. 6)

where ASA_np represents the change in apolar polar area accessible to the solvent (in Ų). The change in enthalpy associated with a process involving a protein also reflects the hydration of the amino acid side chains, together with contributions from either the breakdown or the formation of internal interactions of van der Waals and hydrogen bonds (29). In a previous study, Spolar et al. (30), examining the energetics of binding of ligands and proteins and their relationship to the structural alterations brought about by the binding, found that in all cases where the binding involves a significant conformational change, the absolute values of C_p may be hundreds of cal·K^–1·mol^–1 or even more than 1 kcal·K^–1·mol^–1. The values of C_p for chloride binding to WT and the p.R1306W mutant imply that in both cases a vast apolar surface area (3000 and 1200 A² for WT and p.R1306W mutant, respectively) is buried upon chloride binding, as a consequence of a folding conformational transition, and that this phenomenon is much more evident in WT than in the p.R1306W mutant. These conclusions are in agreement with the results of urea denaturation experiments performed as a function of NaCl. In that case, the m parameter of Equation 1 was indeed found to increase as a function of NaCl for all the VWF constructs used (see Table 1). Because it is known that the m parameter reflects, at least in part, the amount of newly accessible surface area exposed upon denaturation (25), this means that upon urea denaturation, the newly accessible surface area exposed is higher for the Cl^–-bound VWF conformer than for the Cl^–-free form. Cl^– binding, vice versa, inducing a folding conformational transition in the A1-A2-A3 domains, favors a burial of apolar surface area, as emerged from the thermodynamic analysis of the fluorescence data set. Globally taken, these experiments show that chloride binds specifically to the A1 domain of VWF and induces a folding conformational transition with burial of a vast apolar surface area and change of the hydration shell bonded to the surface of the protein.

Hydrolysis of Recombinant VWF Constructs by rADAMTS-13—Several VWF constructs were used to study the effects of chloride on cleavage by ADAMTS-13 as follows: 1) WT A1-A2-A3 domains; 2) p.R1306W A1-A2-A3 domains (2B VWD mutant); 3) WT A1-A2 domain; 4) isolated WT A2 domain; and 5) A2-A3 domain. In all the cases a substrate concentration lower than the K_m value (0.5 µM) was used to meet pseudo-first order conditions. The value of the apparent pseudo-first order rate constant, equal to e₀ k_cat/K_m, was calculated using Equation 3 and then analyzed as a function of chloride concentration. The separation of the hydrolysis products of the various VWF constructs was accomplished by RP-HPLC, using a C4 column. This method allowed the measurement of the pseudo-first order rate constant. Under the low concentration of the various A domains used, which are all below the corresponding K_m values of the interaction with ADAMTS-13, the kinetic rate constant is equal to (k_cat/K_m) times the concentration of ADAMTS-13. By a simple calculation, the k_cat/K_m value was found equal to 7.26 ± 0.2 x 10⁴ M^–1 s^–1, 1.36 ± 0.1 x 10⁵ M^–1 s^–1, and 7.47 ± 0.3 x 10⁴ M^–1 s^–1 for WT A1-A2-A3, p.R1306W A1-A2-A3, and A1-A2 domains, respectively (see Fig. 7, A and B). The value of k_cat/K_m of A2 and A2-A3 hydrolysis was equal to 7.24 ± 0.3 x 10⁴ and 6.56 ± 0.3 x 10⁴ M^–1 s^–1, in good agreement with those recently found by others with similar methods for the hydrolysis of similar A2 and A2-A3 domains (31). The 2B VWD construct p.R1306W is hydrolyzed by ADAMTS-13 faster than the corresponding WT form. This finding shows that when the A1-A2-A3 domains are stabilized by a mutation in a GpIb-bound like conformation, the catalytic interaction with ADAMTS-13 is facilitated, in agreement with recent findings (14).

View larger version (18K): [in this window] [in a new window]   FIGURE 7. A, kinetics of hydrolysis of WT A1-A2-A3 domain (•) and p. R1306W A1-A2-A3 (). B, isolated A2 domain () by 5 nM ADAMTS-13, at 25 °C, pH 8.0, in the absence of NaCl. The concentration of A1-A2-A3 and A2 domain was equal to 0.5µM. The continuous lines were drawn according to Equation 3 with the best fit kcat/Km value of 7.25 ± 0.3 x 104 M–1 s–1, 1.36 ± 0.2 x 105 M–1 s–1 and 7.24 ± 0.4 x 104 M–1 s–1, for WT A1-A2-A3, p.R1306W A1-A2-A3, and A2 domain, respectively.

View larger version (17K): [in this window] [in a new window]   FIGURE 8. Linkage graph showing the kcat/Km values of hydrolysis of WT A1-A2-A3 (•), p.R1306W (), WT A1-A2 (), isolated A2 domain (*), and A2-A3 domains (). The continuous lines were drawn to Equation 4 with the best fit parameter values as follows: k0 = 7.26 ± 0.2 x 104 M–1 s–1, kCl = 1.23 ± 0.3 x 104 M–1 s–1, Kd = 35 ± 5 mM (WT A1-A2-A3); k0 = 1.36 ± 0.1 x 105 M–1 s–1, kCl = 3 ± 0.5 x 104 M–1 s–1, Kd = 158 ± 20 mM (p.R1306W); k0 = 7.47 ± 0.3 x 104 M–1 s–1, kCl = 1.38 ± 0.3 x 104 M–1 s–1, Kd = 36.2 ± 8 mM (A1-A2). No significant NaCl effect was observed for both isolated A2 and A2-A3 domains.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The thermodynamic and kinetic data presented in this study provide strong evidence that the previously discovered conformational effects of chloride ions on VWF multimers (17) occur via specific binding to the A1 domain. The latter is characterized by a / fold, with a -sheet composed of six -strands flanked on each side by three -helices. The ₂/₃ and the ₃/₂ loop have a high B-factor in crystal structures and thus have a flexible conformation (32). In particular, that the A1 domain has a very high conformational flexibility is also confirmed by natural mutations such as I1309V, where the involvement in a hydrogen bond network of an additional water molecule in the inner part of the A1 domain induces at a distance of more than 25 Å a conformational rearrangement of a cluster of basic residues from Lys¹³³² to Arg¹³³⁶, leading to type 2B VWD with enhanced affinity for GpIb (33, 34). In this study, another typical 2B VWD mutant, p.R1306W, shows how a mutation in the A1 domain causes at the same time an enhanced affinity for GpIb, a reduction of chloride affinity, and an enhanced rate of hydrolysis by ADAMTS-13. This finding implies the existence of a conformational linkage between the A1 and A2 domains in the VWF molecule, affecting both chloride and GpIb binding to the A1 domain and ADAMTS-13 interaction at the A2 domain. The p.R1306W natural mutant has an higher affinity for GpIb and the mutation, stabilizing a conformation of the A1 domain in a GpIb-bound like state, reduces at the same time the A1 domain affinity for chloride, as demonstrated previously for the ristocetin-bound conformer of VWF (17). These findings corroborate the hypothesis that a negative thermodynamic linkage does exist between chloride and GpIb binding to VWF (17). Both fluorescence and enzymatic data indicate that the A1 domain bears a chloride-binding site; however, the detailed location of this site remains unclear. Inspection of the crystal structure of the A1 domain in the free and GpIb-liganded conformations (32, 35) reveals that all the positively charged side chains are exposed to solvent. Although the crystal structure of the entire A1-A2-A3 is yet unknown, the structure of the A1 domain (30, 35) and the MD simulation of the A2 domain (36) support the prediction that some of these positively charged residues mediate the interaction between the A1 and A2 domains, presumably forming hydrogen bonds/salt bridges at the interface between the A1 and A2 domains. The thermodynamic data obtained from denaturation studies showed that NaCl enhances the G⁰ value, i.e. the stability of the A1-A2-A3 domains under nondenaturing conditions. The mechanism by which chloride stabilizes the A1-A2-A3 domains could be in part the formation/stabilization of hydrogen bonds/salt bridges between charged residues at the A1-A2 interface upon its binding to a specific site in the A1 domain. Furthermore, because from molecular simulation studies it was shown that the peptide bond Tyr¹⁶⁰⁵–Met¹⁶⁰⁶ in the A2 domain cleaved by ADAMTS-13 is buried in the molecule (36), it may be hypothesized that the "folding" effect of chloride would render more compact the whole A1-A2-A3 domain. This effect would cause the Tyr¹⁶⁰⁵–Met¹⁶⁰⁶ peptide bond to be less available to the catalytic attack by ADAMTS-13, as also experimentally shown. Based on these findings, possible candidates for the anion-binding sites in the A1 domain are likely to be positively charged "clusters" on the surface of the molecule. X-ray diffraction studies on the A1 domain-GpIb complex showed that the ₁/₂ loop of the A1 domain, containing the clusters formed by Lys¹³³² to Arg¹³³⁶ and from Arg¹³⁰⁶ to Arg¹³¹⁵, undergoes allosteric conformational transitions upon GpIb interaction or by mutations causing type 2B VWD (32, 37). Extensive site-directed mutagenesis will be an important tool in addressing the question of whether or not these positively charged residues are involved in the formation of the anion-binding sites. Fluorescence experiments showed that high heparin caused no intrinsic fluorescence of the VWF A1-A2-A3 domains (data not shown) nor did it change at a concentration of 10 µM the apparent affinity of chloride for the A1-A2-A3 domains at 25 °C. This finding would imply that the two clusters of charged residues involved in the formation of the interaction sites for heparin, consisting of one region from Arg¹³⁴¹ to Lys¹³⁴⁸ and from Lys¹⁴⁰⁵ to Lys¹⁴⁰⁸ (38, 39), are not involved in the formation of the chloride-binding site. On the other hand, previous studies showed that heparin accelerates the hydrolysis of VWF by ADAMTS-13 (14), thus having an effect opposite to that exerted by chloride ions. Therefore, functional evidence and spectroscopic evidence are in agreement to show that heparin and chloride ions do not share the same binding site in the A1 domain.

View larger version (9K): [in this window] [in a new window]   FIGURE 9. Bar graph of the effect of NaCl (10 versus 150 mM) on the extent of a 1-min hydrolysis of WT A1-A2-A3 domains by 10 nM ADAMTS-13 at 37 °C under a shear stress of 40 dynes/cm2.

In conclusion, these data show how a physiological inorganic anion, such as chloride, may be involved in the allosteric regulation of a complex macromolecular interaction, such as that between VWF and ADAMTS-13.

	FOOTNOTES

 
^* This work was supported in part by Grant PRIN-2005 from the Italian Ministry of University and Research (to R. D. C.) and a grant from the Fondazione Cariplo (to P. M. M. and F. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Hemostasis Research Centre, Institute of Internal Medicine and Geriatrics, Catholic University School of Medicine, Largo F. Vito, 1, 00168 Rome, Italy. Tel.: 39-6-30154438; Fax: 39-6-30155915; E-mail: rdecristofaro{at}rm.unicatt.it.

² The abbreviations used are: VWF, von Willebrand factor; WT, wild type; RP-HPLC, reverse phase-high pressure liquid chromatography; VWD, von Willebrand disease; HEK, human embryonic kidney.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Chung, D. W., and Fujikawa, K. (2002) Biochemistry 41, 11065–11070[CrossRef][Medline] [Order article via Infotrieve]
2. Furlan, M., Robles, R., and Lämmle, B. (1996) Blood 87, 4223–4234[Abstract/Free Full Text]
3. Anderson, P. J., Kokame, K., and Sadler, J. E. (2005) J. Biol. Chem. 281, 850–857
4. Dong, J. F. (2005) J. Thromb. Haemostasis 3, 1710–1716
5. Dong, J. F., Moake, J. L., Nolasco, L., Bernardo, A., Arceneaux, W., Shrimpton, C. N., Schade, A. J., McIntire, L. V., Fujikawa, K., and Lopez, J. A. (2002) Blood 100, 4033–4039[Abstract/Free Full Text]
6. Ruggeri, Z. M. (1997) J. Clin. Investig. 99, 559–564[Medline] [Order article via Infotrieve]
7. Hoylaerts, M. F., Yamamoto, H., Nuyts, K., Vreys, I., Deckmyn, H., and Vermylen, J. (1997) Biochem. J. 324, 185–191
8. Howard, M. A., and Firkin, B. G. (1971) Thromb. Haemostasis 26, 362–369
9. Read, M. S., Smith, S. V., Lamb, M. A., and Brinkhous, K. M. (1989) Blood 74, 1031–1035[Abstract/Free Full Text]
10. Peterson, D. M., Stathopoulos, N. A., Giorgio, T. D., Hellums, J. D., and Moake, J. L. (1987) Blood 69, 625–628[Abstract/Free Full Text]
11. Ruggeri, Z. M., Pareti, F. I., Mannucci, P. M., Ciavarella, N., and Zimmerman, T. S. (1980) N. Engl. J. Med. 302, 1047–1051[Abstract]
12. DeMarco, L., Mazzucato, M., DeRoia, D., Casonato, A., Fererici, A. B., Girolami, A., and Ruggeri, Z. M. (1990) J. Clin. Investig. 86, 785–792[Medline] [Order article via Infotrieve]
13. Sadler, J. E. (1991) J. Biol. Chem. 266, 22777–22780[Free Full Text]
14. Nishio, K., Anderson, P. J., Zheng, X. L., and Sadler, J. E. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 10578–10583[Abstract/Free Full Text]
15. Colombatti, A., and Bonaldo, E. (1991) Blood 77, 2305 2315[Free Full Text]
16. Hinshelwood, J., and Perkins, S. J. (2000) J. Mol. Biol. 301, 1267–1285[CrossRef][Medline] [Order article via Infotrieve]
17. De Cristofaro, R., Peyvandi, F., Palla, R., Lavoretano, S., Lombardi, R., Merati, G., Di Stasio, E., and Mannucci, P. M. (2005) J. Biol. Chem. 280, 23295–23302[Abstract/Free Full Text]
18. Hilbert, L., Gaucher, C., de Romeuf, C., Horellou, M. H., Vink, T., and Mazurier, C. (1994) Blood 83, 1542–1550[Abstract/Free Full Text]
19. Baronciani, L., Cozzi, G., Canciani, M. T., Peyvandi, F., Srivastava, A., Federici, A. B., and Mannucci, P. M. (2003) Blood Cells Mol. Dis. 30, 264–270[CrossRef][Medline] [Order article via Infotrieve]
20. Baronciani, L., Federici, A. B., Beretta, M., Cozzi, G., Canciani, M. T., and Mannucci, P. M. (2005) J. Thromb. Haemostasis 3, 2689–2694
21. Andrews, R. K., Gorman, J. J., Booth, W. J., Corino, G. L., Castaldi, P. A., and Berndt, M. C. (1989) Biochemistry 28, 8326–8336[CrossRef][Medline] [Order article via Infotrieve]
22. Bolen, D. W., and Santoro, M. M. (1988) Biochemistry 27, 8069–8074[CrossRef][Medline] [Order article via Infotrieve]
23. Spolar, R. S., Livingstone, J. R., and Record, M. T. (1992) Biochemistry 31, 3947–3955[CrossRef][Medline] [Order article via Infotrieve]
24. Chen, Y., and Barkley, M. D. (1998) Biochemistry 37, 9976–9982[CrossRef][Medline] [Order article via Infotrieve]
25. Baskakov, I. V., and Bolen, D. W. (1999) Protein Sci. 8, 1314–1319[Medline] [Order article via Infotrieve]
26. Ptitsyn, O. B. (1995) Trends Biochem. Sci. 20, 376–379[CrossRef][Medline] [Order article via Infotrieve]
27. Hubbard, S. J. (1998) Biochim. Biophys. Acta 1382, 191–206[CrossRef][Medline] [Order article via Infotrieve]
28. Collins, K. D. (2004) Methods (Amst.) 34, 300–311
29. Livingstone, J. R., Spolar, R. S., and Record, M. T., Jr. (1991) Biochemistry 30, 4237–4244[CrossRef][Medline] [Order article via Infotrieve]
30. Spolar, R. S., Ha, J.-H., and Record, T. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8382–8385[Abstract/Free Full Text]
31. Zanardelli, S., Crawley, J. T. B., Chion, C. K. N. C. K., Lam, J. K., Preston, R. J. S., and Lane, D. A. (2006) J. Biol. Chem. 281, 1555–1563[Abstract/Free Full Text]
32. Dumas, J. J., Kumar, R., McDonagh, T., Sullivan, F., Stahl, M. L., Somers, W. S., and Mosyak, L. (2004) J. Biol. Chem. 279, 23327–23334[Abstract/Free Full Text]
33. Celikel, R., Ruggeri, Z. M., and Varughese, K. I. (2000) Nat. Struct. Biol. 7, 881–884[CrossRef][Medline] [Order article via Infotrieve]
34. Varughese, K. I., Celikel, R., and Ruggeri, Z. M. (2002) Curr. Protein Pept. Sci. 3, 301–312[CrossRef][Medline] [Order article via Infotrieve]
35. Emsley, J., Cruz, M., Handin, R., and Liddington, R. (1998) J. Biol. Chem. 273, 10396–10401[Abstract/Free Full Text]
36. Sutherland, J. J., O'Brien, L. A., Lillicrap, D., and Weaver, D. F. (2004) J. Mol. Model. 10, 259–270[CrossRef][Medline] [Order article via Infotrieve]
37. Miyata, S., Goto, S., Federici, A. B., Ware, J., and Ruggeri, Z. M. (1996) J. Biol. Chem. 271, 9046–9053[Abstract/Free Full Text]
38. Rastegar-Lari, G., Villoutreix, B. O., Ribba, A. S., Legendre, P., Meyer, D., and Baruch, D. (2002) Biochemistry 41, 6668–6678[CrossRef][Medline] [Order article via Infotrieve]
39. Adachi, T., Matsushita, T., Dong, Z., Katsumi, A., Nakayama, T., Kojima, T., Saito, H., Sadler, J. E., and Naoe, T. (2006) Biochem. Biophys. Res. Commun. 339, 1178–1183[Medline] [Order article via Infotrieve]
40. Lämmle, J. A., Kremer Hovinga, A., and Alberio, L. (2005) J. Thromb. Haemostasis 3, 1663–1675
41. Nolasco, L. H., Turner, N. A., Bernardo, A., Tao, Z., Cleary, T. G., Dong, J.-F., and Moake, J. L. 2005 Blood 106 4199–4209[Abstract/Free Full Text]
42. Federici, A. B., Mannucci, P. M., Stabile, F., Canciani, M. T., Di Rocco, N., Miyata, S., Ware, J., and Ruggeri, Z. M. (1997) Thromb. Haemostasis 78, 1132–1137[Medline] [Order article via Infotrieve]
43. Hassenpflug, W. A., Budde, U., Obser, T., Angerhaus, D., Drewke, E., Schneppenheim, S., and Schneppenheim, R. (2006) Blood 107, 2339–2345[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. S. Buzza, J. M. Dyson, H. Choi, E. E. Gardiner, R. K. Andrews, D. Kaiserman, C. A. Mitchell, M. C. Berndt, J.-F. Dong, and P. I. Bird Antihemostatic Activity of Human Granzyme B Mediated by Cleavage of von Willebrand Factor J. Biol. Chem., August 15, 2008; 283(33): 22498 - 22504. [Abstract] [Full Text] [PDF]

				W. Gao, P. J. Anderson, E. M. Majerus, E. A. Tuley, and J. E. Sadler Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease PNAS, December 12, 2006; 103(50): 19099 - 19104. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 281/41/30400    most recent M603321200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Cristofaro, R. Articles by Mannucci, P. M. Search for Related Content PubMed PubMed Citation Articles by De Cristofaro, R. Articles by Mannucci, P. M. Social Bookmarking                      What's this?